Abstract
Breast cancer is the leading cancer and the second leading cause of mortality in women in most European countries, North America, and Australia. In Europe, 1 out of every 10–15 women will develop breast cancer in her lifetime, and the risk is even higher in the United States, where it is 1 out of every 8 women.
PET-CT was shown to be useful for detecting recurrence in breast cancer patients, for restaging, and for treatment response assessment. Therefore, 18 F-FDG PET-CT has become more widely adopted in selected categories of patients, where PET is complementary to breast MRI resulting in both modalities to be part of patient clinical workup. On those patients, the emergence of hybrid PET-MR scanners offers the advantage of combining both studies in a single session, reducing radiation dose of CT and allowing more accurate localization of lesion detection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kuhl C (2007) The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 244(2):356–378
Kuhl CK (2007) Current status of breast MR imaging. Part 2. Clinical applications. Radiology 244(3):672–91
Biglia N et al (2011) Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. Eur J Surg Oncol 37(3):199–204
Moy L et al (2010) Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer. Breast J 16(4):369–376
Koolen BB et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131(1):117–126
Alberini JL et al (2009) 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 115(21):5038–5047
Carkaci S et al (2009) Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 50(2):231–238
Pennant M et al (2010) A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 14(50):1–103
Ueda S et al (2011) Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer 18(4):299–308
Duch J et al (2012) PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer. Q J Nucl Med Mol Imaging 56(3):291–298
Duch J et al (2009) 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 36(10):1551–1557
Vargas MI et al (2013) Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies. MAGMA 26(1):57–69
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Tabouret-Viaud, C., Baskin, A., Beer, A.J., Eiber, M., Gerngross, C., Loubeyre, P. (2013). Breast Cancers. In: Ratib, O., Schwaiger, M., Beyer, T. (eds) Atlas of PET/MR Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-31292-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-31292-2_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-31291-5
Online ISBN: 978-3-642-31292-2
eBook Packages: MedicineMedicine (R0)